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Abstract
Background: Inhabitants of Guadeloupe are chronically exposed to low doses of chlordecone via local food due
to its past use in banana plantations. The corresponding health impacts have not been quantified. We develop a
quantitative method and present the results in two articles: 1. Hazard identification, exposure-response functions,
and exposure, 2. Health impacts, and benefits of a program to reduce the exposure of the population. Here is the
second article.
Methods: The exposure-response functions derived in Part 1 (for liver and prostate cancer, renal dysfunction and
cognitive development) are combined with the exposure data to calculate the impacts. The corresponding costs
are calculated via DALY’s and VOLY. A no-effect threshold is included via the marginal fraction of the collective
exposure above the reference dose. The health benefits are the impacts in 2002 (before the exposure reduction
program) minus the impacts in 2006 (since the program). They are compared to the costs, namely the public
annual expenditures for reducing the population exposure.
Results: Without threshold, estimated annual cases of liver cancer, prostate cancer and renal dysfunction are
respectively 5.4, 2.8, 0.10 in 2002; and 2.0, 1.0, 0.04 in 2006. Annual IQ points lost (cognitive development) are
respectively: 1 173 and 1 003. The annual cost of total impacts is 38.3 Million Euros (M€) in 2002 and 23.7 M€ in
2006. Comparing the benefit of 14.6 M€ with the 3.25 M€ spent for prevention, the program appears well justified.
With threshold, the costs of the impacts are lower, respectively: 26.5 M€ in 2002 and 12.8 M€ in 2006, but the
benefit is not very different: 13.7 M€.
Conclusion: This is the first study that quantified chronic non genotoxic effects of chlordecone exposures in
Guadeloupe. According to our results, preventive actions should be focused on pregnant women because of the
high social cost of development impairment and also because their exposures decreased less rapidly than others.
Prevention effort should be sustained as long as chlordecone remains in soils. Additional toxicological and
epidemiological research would also be required for health endpoints that could not be taken into account
(neurotoxicity of adults, autoimmune diseases and other developmental effects).
Keywords: Chlordecone, Low-dose, Threshold, Risk assessment, Non-mutagen agent, Endocrine disrupter,
Risk management, Exposure reduction program
* Correspondence: vincent.nedellec3@gmail.com
1Director of Vincent Nedellec Conseil, 23, rue André Masséna–83000, Toulon,
France
Full list of author information is available at the end of the article
© The Author(s). 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Nedellec et al. Environmental Health  (2016) 15:78 
DOI 10.1186/s12940-016-0159-3
Background
Chlordecone has been used as pesticide for banana plan-
tations. The inhabitants of the French West Indies are
chronically exposed to low doses of chlordecone via
local food. The corresponding public health issues have
not been satisfactorily quantified because of the lack of
an appropriate risk assessment method. Nonetheless,
several million euros have been invested every year since
2003 for the reduction of exposure in Martinique and
Guadeloupe [1–3]. Official investigations had revealed
that 1.3 % of adults in Guadeloupe were exposed above
the “no effect threshold dose” (the reference dose RfD)
of 0.5 μg/kg/d [4]. Exposure to chlordecone seems more
common in children 3 to 5 years old than in adults, with
up to 18.5 % above RfD in Martinique [5]. These estimates
of ingestion exposures are based on food consumption
survey data matched with the results of chlordecone mea-
surements in food made for the screening and control
program. The main activities of the control program are
to withdraw food from the market and water from the dis-
tribution system when chlordecone is above the limit
values [6]. However, some polluted food from individual
gardens could be eaten by the owners or the relatives and
friends because they escape the market control system. It
is very likely that chlordecone has also been used in other
tropical countries, but no other studies have been carried
out to assess its impacts.
The RfD is based on a chronic animal study that ob-
served an increase in kidney damage (glomerulosclerosis)
in female Wistar rats [7]. However, monitoring of poi-
soned workers manufacturing chlordecone in the USA
(Hopewell and Baltimore) revealed no renal function im-
pairment [8, 9]. In addition, a recent study showed that
only mouse strains predisposed to auto immune diseases
developed kidney lesions after ingesting chlordecone [10].
Accordingly, the hazards of chlordecone in people with
exposure above this RfD are uncertain, and the results of
exposure studies are difficult to translate into public health
decisions. In particular, they do not provide answers to the
following questions:
 What effect will occur in persons exposed above
RfD: that observed at the lowest dose tested in
animals, other effects known at some higher doses,
or even the effect of another ubiquitous pollutant
that is enhanced by chlordecone?
 If exposure exceeds the RfD what is the likelihood
that an effect occurs?
 Are we sure that there will be no effect from
exposures below RfD?
Several epidemiological studies have recently been car-
ried out in Guadeloupe. The results show that chronic
low exposure to chlordecone, mainly below the value of
the RfD, is correlated with an increased risk of prostate
cancer in men over 45 years [11] and with impaired neu-
robehavioral development in the young child [12, 13].
Other effects were investigated but were not significantly
associated with low exposure to chlordecone: change in
sperm quality [14, 15], and the rate of circulating hor-
mones in men [16]. No studies looked at possible kidney
damage, the critical effect found in laboratory animals
[17, 18] nor at liver cancer which is significantly in-
creased in a chronic animal study by the NCI [19]. The
latter is used by the US-EPA to develop a cancer slope
factor. In epidemiological studies exposure was estimated
via blood chlordecone concentration (Cl-b).
Another concern for chlordecone health risk assessment
is that we do not know sufficiently well the correspond-
ence between Cl-b and the dose by ingestion expressed as
mg/kgBW. First, an ad hoc study in Guadeloupe published
in 2010 found that exposure data based on food consump-
tion combined with food concentration of chlordecone are
poorly correlated (R2 = 0.20) with blood chlordecone [20].
Second, there was no PBPK (physiologically based phar-
macokinetic) model available at the time of the literature
search that could help to convert a dose by ingestion into
a blood concentration of chlordecone.
Health risk assessment cannot be quantitative without
a quantitative relationship between exposure and response.
They are commonly available for carcinogenic effects but
not for other effects that have a non-genotoxic mode of ac-
tion. To quantify the public health impacts of chlordecone
in Guadeloupe exposure-response functions (ERFs) are ne-
cessary. Following the recommendations of the Silver Book
[21], we assume that non-genotoxic effects can occur at
low doses if the mode of action has been found to be active
at low doses and is shared by a frequent human disease or
a ubiquitous chemical. In that case exposure-response
functions, similar to those for genotoxic carcinogens, can
be derived for non-genotoxic effects. Our objective is to
develop a methodological framework based on: 1. the se-
lection of potential hazards from low dose exposures; 2.
deriving ERFs from human or animal data; 3. evaluation of
health and economic impacts; 4. compare costs of the ex-
posure control program with public health gains resulting
from the decrease in population exposure. Because of their
length, methods and results are described in two separate
articles. Here is the second article whose objectives are: 1)
to assess the health risks corresponding to chlordecone
exposure in Guadeloupe before and after implementation
of the exposure reduction public program, 2) estimate the
health impacts and costs, 3) compare the health benefits
(defined as the difference in impacts before and after pre-
ventive actions) and the costs of the program.. The overall
objective is to carry out a cost-benefit analysis of the
exposure control program that has been implemented
in Guadeloupe since 2003, i.e. compare its cost with
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the benefit of reduced health impacts. Since the IOM
report in 1981 [22], it is widely accepted that the cost
of environment-related health effects should be consist-
ently evaluated for decision making in public health,
and a great deal of research has been carried out since
then to develop and improve the required methods. Of
particular importance are two major governmental
projects, one in the EU, the other in the USA, that have
become de facto guidelines [23, 24]. Here we apply the
methods of ExternE for the impacts of chlordecone,
with updated monetary values for mortality [25].
Methods
Results from Part 1
The methods used for identification of hazards at low
doses of chlordecone and for derivation of the correspond-
ing exposure-response functions (ERFs) were presented in
Part 1. Briefly, with that methodology we found four pos-
sible effects at chronic low chlordecone dose: cancers, de-
velopmental impairment, hepatotoxicity, and neurotoxicity
in adults. For neurotoxicity in adults the lack of a quantita-
tive study precludes ERF derivation. With the traditional
approach of public health agencies renal toxicity is consid-
ered as the critical effect; therefore we also derive an ERF
for this effect. Two of these ERFs were derived from animal
studies: kidney damage (ERF = 0.0022 mg/kg/d) [7] and
liver cancer (ERF = 2.69 per mg/kg/day) [19]. The two
others were derived from recent epidemiological stud-
ies: prostate cancer in men over the age of 44 years
(ERF = 0.0019 mg/lblood) [11] and impairment of cognitive
development in boys (ERF = −0.32 IQpoint per μg/lcord-blood)
[12, 13]; for girls the associations with cognitive develop-
ment were not significant. The four ERFs are based on ab-
solute risk (or excess risk), they are used without the need
to know the background incidence in the population. The
cancer ERFs are adjusted for a standard lifetime exposure
of 70 years.
Exposures of the Guadeloupe population are known
thanks to blood chlordecone assays conducted for
epidemiological studies. They have been described in
Part 1. Briefly, the available data relate to two separate
periods of time: before 2003, and after 2003 when
preventive actions started. They are expressed in μg of
chlordecone per liter of blood (μg/Lblood). The quar-
tiles used to describe the distribution of exposures in
the population come from a review article [26].
For prostate cancers and cognitive development the
ERFs are based on blood chlordecone; it will be marked
by a subscript “b” added to the ERF and to the exposure
“Exp”. The ERFs for liver cancer and kidney damage are
based on ingested doses, marked by a subscript “i” for
ERF and Exp. A conversion factor between ingestion
dose and blood chlordecone was derived from the available
pharmacokinetic data (see Part 1). Briefly, they showed a
half-life of blood chlordecone in humans ranging from 63
to 192 days with an average of 127.5 days. The conversion
factor (CF) obtained according to a biphasic (uptake/excre-
tion) linear model is: CFmean = 0,064 (μg/kg/d)/(μg/L), with
lower and upper limits CFmin. = 0,043 (μg/kg/d)/(μg/L) and
CFmax. = 0,131 (μg/kg/d)/(μg/L).
Health impact assessment
This begins by calculating the excess risk for chronic
effects of chlordecone exposure with the following
equations:
ER ¼ ERFb  Expb ð1Þ
ER = excess risk for a given exposure level (unitless)
ERFb = exposure-response function based on blood
chlordecone ((μg/Lblood)
−1)
Expb = exposure level based on blood chlordecone
(μg/Lblood)
ERFb ¼ ERFi=CW  CFi=b ð2Þ
ERFb = ERF based on blood chlordecone ((μg/Lblood)
−1)
ERFi = ERF based on ingestion dose ((mg/kg/d)
−1)
CW = conversion factor for mass units: 1000 μg/mg
CFi/b = conversion factor between ingestion dose and
blood chlordecone (μg/kg/d)/(μg/L)
Health impacts are defined as the number of cases due
to population exposure. They are calculated for one year
of exposure simply by multiplying the number of people
at risk by the value of the excess risk:
I ¼ ER  n ð3Þ
I = impact (number of cases)
ER = excess risk for a given exposure level (−)
n = number of people at risk
The impacts, being subsequently monetized with the
value of a life year lost (VOLY), must be expressed as
equivalent number of deaths, except for impairment of
cognitive development for which the monetary value is
based on the loss of lifetime income. The ERFs for liver
cancer and for kidney damage are based on animal num-
ber of deaths in the studies. The one for prostate cancer
is based on human incidence of new cases. The annual
number of new cases of prostate cancer is very different
from the annual number of deaths. The Guadeloupe
data indicate a ratio of 4.7 between new cases and deaths
[27]. Thus, the impact expressed as number of deaths
from prostate cancer must be 4.7 times smaller than the
impact estimated as number of new cases.
The ERF for liver cancer applies to all individuals in
the population regardless of age; the ERF for prostate
cancer only applies to men older than 44 years and the
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ERF for kidney damage only to women of all ages. The
ERF for impaired cognitive development applies to male
newborns.
Each of these population categories is divided into 5
exposure groups, characterized by the average interquar-
tile value (Part 1). The first group includes individuals
whose exposure is between 0 and the value of the analyt-
ical detection limit (DL). The second group includes in-
dividuals whose exposure is greater than the DL and
lower than percentile 25 (P25). The proportion of indi-
viduals in this group is variable and is 25 % minus than
the proportion of individuals in the first group. The
third group includes the 25 % of the population whose
exposure is between P25 and P50; the two last groups
are analogous. The numbers of individuals in each popu-
lation category come from national census data for
Guadeloupe [28]. For the period before 2003, the refer-
ence year is 2002 and for the period after 2003, the ref-
erence year is the 2006. INSEE gives an annual growth
rate of the population between 1999 and 2005 of 1.2 %.
The figures for 2006 are extrapolated from 2005 with
growth of 1.2 %. In Guadeloupe in 2002 the numbers in
the population categories are approximately 437,000
persons (for liver cancer), 227,500 women (for kidney
damage), 72,500 men over 44 years (for prostate cancer),
and 3,750 newborn boys (for cognitive development). In
2006 the corresponding numbers are respectively 458,000;
239,500; 76,050; and 3,930.
Consideration of a no effect threshold
A strong assumption of our main approach is to consider
the effects of chlordecone without “no-effect threshold”. It
is, however, interesting to see what happens if a threshold
is introduced. The true collective no-effect threshold is
not known. For illustration here we consider it equal to
the reference value derived by the health and safety
agencies: 0.5 μg/kg/day for adults. We derive a refer-
ence dose for effects on development, 0,165 μg/kg/day,
as the average of two reference doses (RfD) found in the
US-EPA toxicological profile of chlordecone regarding de-
velopmental effects [18]. One study shows, in Wistar rat
exposed in utero via maternal diet, a reduced body weight
gain 100 days after birth (RfD = 0.03 mg/kg/day; Squibb,
1982), the second shows in mice, with the same exposure
pathway, a significantly reduced litter size (RfD = 0.3 mg/
kg/day; Good, 1965). This threshold of 0.165 mg/kg/day
applies to the exposure of pregnant women and not to the
newborn.
A simple and rough way to introduce a threshold in
the calculation of impacts would be to multiply the results
obtained without threshold by the proportion of the popu-
lation exposed above the threshold. However, regardless of
the true form of the exposure response relationship, it is
not the population fraction above threshold that matters,
but rather the portion of the collective exposure that is
above the threshold [29]. The collective exposure is the
sum of ei individual exposures of the population. A log-
normal distribution has been found to be best general
model for the distribution of environmental pollutant ex-
posures [30]. The fraction of the collective exposure that








Fthr = fraction of collective exposure that is above the
threshold (−)
p = total population
pthr = number of individuals with exposure ≤ threshold
ei = exposure of individual i, in order of increasing i.
The impacts with a no effect threshold are obtained by
multiplying the impacts without threshold by Fthr:
Ithr ¼ I  Fthr ð5Þ
Ithr = impact with threshold (number of cases)
I = impact without threshold dose (number of cases)
Fthr = collective fraction of exposure above the thresh-
old (−)
Assessment of Benefits and Costs
For chronic risk the best approach may be based on
disability-adjusted life years (DALY) and value of life
year (VOLY) concepts [30, 31]. One DALY can be
thought of as one lost year of “healthy” life. DALYs used
here come from the WHO estimates for France during
the years 2000 and 2012 [32, 33]. In our study, the refer-
ence year for all monetary values is 2006. Between 2000
and 2012 there has been some shift in DALY’s values.
The observed trend is due to changes in incidence rates,
mortality rates and age at death. To obtain the 2006
value we have made a simple interpolation between 2000
and 2012 values. This is possible because the WHO
method has not changed between 2000 and 2012 [34].
DALY attributable to liver cancers, prostate cancers and
kidney damage are respectively: 21.9 yr/case 16.5 yr/case
and 26.1 yr/case.
Several methods exist for estimating the cost of mortal-
ity. The OECD recommends basing cost-benefit studies
for public policy on contingent valuation surveys for the
willingness-to-pay to avoid a premature death [35]. How-
ever, for the VOLY needed for most pollution impacts, in
particular of chlordecone, not enough contingent valu-
ation surveys have been carried out and their results are
not sufficiently consistent. For that reason the guidelines
for France published by the Commission chaired by
Quinet [25] recommend that VOLY should be derived
from the Value of Statistical Life for which reliable
Nedellec et al. Environmental Health  (2016) 15:78 Page 4 of 13
numbers have been provided by OECD [35]. We agree
with the recommendations of Quinet. They imply a
VOLY of 111 327 € in 2006, after adjustment for inflation.
Knowing the number of DALY per case and the value of a
VOLY one can simply estimate the cost of a case by multi-
plying the DALYs by VOLY. The cost of the impact I is
calculated using the following equation:
CI ¼ I  DALY  VOLY ð6Þ
CI = Cost of Impact (€/y)
I = impact with or without threshold dose (annual
number of cases)
DALY =Disability Adjusted Life Year (y/cases)
VOLY = Value of Life Year (€/y)
The DALY approach is not used for impaired cognitive
development, because there is no clear correlation be-
tween IQ level and life expectancy. Some studies have
shown an inverse correlation between IQ and the risk of
premature death (death before age 50), but the statistical
association disappears if adjusted for the socio-economic
level of the person [36, 37]. Conversely, in the same
study, the correlation between socio-economic level and
risk of premature death is not influenced by the level of
IQ. On the other hand, North American studies on lead
exposure of children have shown a strong link between
loss of IQ points in childhood and loss of the lifetime
income. The implied value of an IQ point in the North
American studies was extrapolated to France to yield the
cost of 1 lost IQ point as 17 363 €2008 (value in 2008)
[38]. This value was used without modification to assess
the economic impacts associated with mercury exposure
in Europe [39]. So we assume the hypothesis that this
value also applies to IQ points lost by chlordecone ex-
posure. Given the inflation rate between 2006 and 2008
this value becomes: 16 837 €2006/IQpoint. The unit costs
of the four impacts included in our study are presented
in Table 1.
The benefits of prevention can be estimated in physical
terms, as number of cases avoided, or in monetary terms,
as avoided costs, avoided referring to the difference made
by the prevention program. The implementation of the
prevention program starts in 2003 (Part 1). The ERF being
linear, the number of cases prevented is directly propor-
tional to the decrease in exposures. We estimate the bene-
fits attributable to the program as the difference between
the cost of impacts in 2002 (before 2003) and cost of
impacts in 2006 (after 2003).
In 2012 the government published an evaluation of the
exposure reduction program costs for the years 2008–
2010 [40]. The program involves a wide variety of activ-
ities, such as monitoring of water wells and closure of
polluted wells, monitoring of soils and limiting the
planting of polluted soils, monitoring of food and re-
moving polluted food from the market; the program also
includes information campaigns, for farmers and home-
owners about growing of food. It is not known how
much exposure reduction is attributable to each of these
actions. Annex 5 of the report shows the costs for the
activities carried out in Martinique and Guadeloupe. The
population of these two islands being roughly equivalent,
we take the expenditures for Guadeloupe to be half of the
total. The spending over three years was 20.7 million €
or 6.9 million €/year and about 3.45 million €/year for
Guadeloupe. Adjusted for inflation this value becomes:
3.25 million €2006/year for 2006.
Uncertainties
As usual in this field, the models and parameters are more
or less uncertain. A rigorous analysis of the uncertainty of
the result would necessitate estimating the uncertainty
distributions of all the parameters and models, and carry-
ing out a Monte Carlo calculation to obtain the uncer-
tainty distribution of the result. Such a task is even more
difficult and uncertain than the calculation of central
values and beyond the scope of this paper (see Chapter 11
of [30]).
However, one can obtain at least a rough first indication
of the uncertainties by focusing on the most uncertain ele-
ments of the calculation, because elements with relatively
small uncertainties have only a small effect on the overall
uncertainty of the result. In our work the most uncertain
elements are the exposure-response function (ERF), the
assumption about a possible threshold, and the estima-
tion of exposure (ingestion dose or blood chlordecone).
For each of these we will show how much the results
Table 1 Unit values for the monetarization of health impacts
Health outcome DALYa (yr/case, France 2006) VOLYb (€2006) Unit value = DALY × VOLY (€2006)
Liver cancer (per case) 21.9 111 327 2 441 030
Prostate cancer (per case) 16.5 111 327 1 835 523
Renal dysfunction (per case) 26.1 111 327 2 902 790
Cognitive development (per IQ point) na na 16 837
aDisability adjusted live year, from WHO, 2014 [32, 33]
bValue of Life Year, From Quinet [25], after adjustment for inflation
Na: not appropriate
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are changed by different assumptions: in Table 2 for
the ERF, in Tables 3 and 4 for the threshold.
For liver cancer, the conversion from ingestion dose to
blood chlordecone varies by a factor of 3. Since this fac-
tor is larger than the factor between the smallest and the
largest BMD (=2.1; see Table 4 in Part 1) and between
male and female best BMDs (Tables 3 and 4 in Part 1),
we use a factor 3 to represent the uncertainty of the ERF
of liver cancers. For prostate cancer the most uncertain
parameter in the ERF is the 95 % confidence interval
(95 % CI) around the risk differential (OR-1): central
value = 0.77; lower limit = 0.21: and upper limit and 1.58.
That is a factor 7.5 between the lowest value and the
highest. For kidney damage the difference between the
smallest and largest acceptable BMD10-HED gives a factor
of 29 (see Part 1). This factor being greater than that of
the conversion factor, we take it as the uncertainty of
the ERF kidney damage. For cognitive development the
main uncertainty comes from the conversion of the ASQ
scores (Age and Stage Questionnaire) measured at ages 7
and 18 months in the epidemiological study [12, 13] to
IQ points, required for the monetary valuation. Such a
conversion is obviously problematic because different
aspects of cognitive abilities are measured. But there is
no alternative because these ASQ scores are the only
available quantitative data on the developmental neuro-
toxicity of chlordecone in humans. For the conversion
factor we assume that 1 ASQ point = 1 IQ point as central
value, with lower and upper bounds 0.2 IQ points and 2
IQ points, an interval that extends over a factor of ten.
However, the reality of neurotoxic effects of chlordecone
is not in doubt, because toxicological studies have identi-
fied relevant pathways for such effects in the body.
Results
The health impacts without threshold, and the associated
costs and benefits attributable to prevention are presented
in Table 3 (details in Additional file 1). The benefits are sig-
nificant, in physical and in monetary terms. For instance,
the number of deaths from liver cancer before 2003 is
estimated at 5.4/yr and after 2003 at 2.0/yr. That is 3.4
deaths/yr avoided by reducing the exposure. Before
2003, the total cost of health impacts (see Table 3)
amounted to 38.3 million €2006/yr (denoted by M€/yr)
(range from 14.2 to 77.7). Before 2003, impacts on cog-
nitive development are the most important with 52 %
of the total annual cost, followed by liver cancer (34 %),
prostate cancer (13 %) and kidney damage (0.8 %). After
2003, the total cost of impacts is reduced to 23.7 M€/yr
(from 7.2 to 47.8). The part of cognitive development in
the total cost after 2003 increases to 71 %. This indicates a
smaller decrease of in utero exposures compared to the
decrease of others population exposures. Overall, the ben-
efits due to the reduction of exposures are estimated at
14.6 M€/yr (from 7.0 to 30.0 M€/yr). The percentages of
the total benefits are: liver cancer 56 %, cognitive develop-
ment 23 %, prostate cancer 20 % and renal disease 1.2 %.
Thus, with this calculation the annual total benefits
are 4.5 times higher than annual cost of prevention
(3.25 M€/yr).
Since cognitive development is the most uncertain im-
pact, we note that if it were omitted entirely from the
analysis, the benefit would be reduced from 14.6 M€/yr
to 11.8 M€/yr, still 3.6 times as large as the cost.
Results obtained with threshold are presented in Table 4
(details in Additional file 1). The collective exposure frac-
tions above threshold (Fthr) in adults are higher (31 to
64 %) in the period before 2003 than after (24 to 34 %).
They are also higher in men, respectively before and after
2003: 64 % and 34 %, than in women respectively 31 %
and 24 %. However, they have dropped less in women than
in men. The no-effect threshold dose for newborns being
lower (0.165 versus 0.5 μg/kg/d), the Fthr are significantly
higher. The decrease in Fthr for newborns after 2003 is
lower than in men. The cost of impacts before 2003 to-
taled 26.5 M€/yr (from 8.5 to 53.5), about 69 % of the cost
of impacts without threshold. The effects on cognitive de-
velopment are the most important with 64 % of the total
annual cost, followed by liver cancer (23 %), prostate can-
cer (12 %) and kidney damage (0.4 %). After 2003, the cost
of impacts with threshold amounted to 12.8 M€/yr (from
3.3 to 25.8), about 54 % of the cost of impacts without
threshold. The part of impaired cognitive development in-
creases for the same reason as above. Overall, the benefits
due to the reduction of exposures are estimated at 13.7 M
€/yr (from 5.2 to 27.8). They are very close to the benefits
calculated without threshold. They rank as follows: cogni-
tive development 45 %, liver cancer 35 %, prostate cancer
Table 2 The most uncertain parameters in the ERFs of chronic chlordecone effects
Health outcome Most uncertain parameter Unit Mean valuea Low valuea High valuea Ratio high/low value
Liver cancer CFi/b (μg/kg/d)/(μg/L) 0.064 0.043 0.131 3.05
Prostate cancer OR-1 (−) 0.77 0.21 1.58 7.52
Renal dysfunction BMD10-HED (mg/kg/d)
−1 0.013 0.001 0.032 28.87
Cognitive development IQ to ASQ equivalence IQpt/ASQpt 1 0.2 2 10.00
CFi/b: conversion factor of ingestion dose to blood concentration of chlordecone. OR-1: difference of risk in exposed and reference populations. IQ to ASQ equivalence:
IQ equivalence of 1 point of fine motor skill score in Age and Stage Questionnaire
aTaken from Part 1
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20 % and renal disease 0.5 %. Thus, the annual total bene-
fit estimated with a threshold dose is 4.2 times higher than
the annual cost of prevention (3.25 M€/yr).
Discussion
We have implemented the recommendations of the Silver
Book of the National Research Council of the USA [21]
and obtained exposure-response functions that make it
possible to quantify the health risks of chlordecone, both
carcinogenic and non-carcinogenic. We have calculated
the cost of these health impacts using the methods of en-
vironmental economics, with specific monetary values rec-
ommended by Pichery [38] and Quinet [25]. We have
calculated these costs before and after the implementation
of the exposure reduction program. Thus we have been
able to compare the benefit of this program with its cost
(as reported in [40]). We find that the exposure reduction
program is very well justified, whether or not one includes
a no-effect threshold. The benefit is at least four times lar-
ger than the cost: the program appears well justified.
The methodology is general and can be used for other
environmental pollutants.
One may, however, wonder if the uncertainties could
invalidate the conclusion. There are two kinds of uncer-
tainty, one related to measurement error and one related
to lack of knowledge. The uncertainties of all the variables
and assumptions in our model combine to determine the
uncertainty of the results. A rigorous analysis would re-
quire Monte Carlo calculations, see for instance Chapter
11 of Rabl 2014 [30]. Here we opted for a much simpler
approach, taking into account only the factor that is the
most uncertain in the ERF: the OR for risk of prostate
cancer, the ingestion dose to blood chlordecone (CFi/b)
conversion factor for liver cancer, the BMD10-HED for kid-
ney damage, and finally the equivalence between IQ points
and ASQ points for impaired cognitive development (see
Table 2). We also consider that the measurement errors
are smaller and included in the natural variation of the
parameters. For example, the measurement error in
blood chlordecone concentrations is less than 20 % (see
appendix in Multigner et. al. 2010), whereas the range
of measured values is a factor of 177 in the prostate
cancer study (0.24 to 44.4 μg/l). Hence, this range repre-
sents very well the combination of measurement error and
natural variability. The variability of exposures is taken into
account by decomposition into groups corresponding to
exposure quartiles. This option has been preferred to the
use of a central value (average or median) with confidence
interval because of the very skewed shape of the distribu-
tion of exposures. The costs are framed by low and high es-
timates representing the variability of the most variable
parameter in the model.
To explain the uncertainties related to the lack of
knowledge, recall that our main model has six parameters:
the ERF, the conversion factor of ingestion dose to blood
concentration, exposures, the number of people at risk,
the DALY values and the VOLY value. The alternative cal-
culations with threshold have a further parameter: the
fraction of collective exposure above the threshold (Fthr).
Uncertainties related to ERF were discussed in the previ-
ous article (Part 1). Briefly, they contain neither safety fac-
tor nor uncertainty factor. Their points of departure
(POD) are the central estimate of the risk indicators in the
original studies. When multiple POD are possible, we do
not choose one that will give the strongest slope, but the
average POD. This makes it unlikely to overestimate risk
in the range of known exposures. However, the linear ex-
trapolation from the POD to the origin, may overestimate
risk if the true shape of the dose–response relationship
is sub-linear or has a no-effect threshold. The case of a
potential threshold is discussed later. Concerning a
sub-linear form, an overestimate is unlikely for prostate
cancer because the ERF retained here derives from the
most exposed group. The ERFs from the two lower exposed
groups would be much higher (see Part 1 Table 1). As
shown in Figure 1 of Part 1, the regression of the three
ERFs is an inverted hockey stick curve, clearly supra-linear.
This kind of exposure-response relationship is known in
other endocrine disruptors [41]. Likewise we can assume
that kidney damage and reduced cognitive development,
two other effects of chlordecone mediated by endocrine
mechanisms are in the same situation. For liver cancer the
only available point of comparison is the cancer slope factor
(Sf ) derived by the US-EPA from the same study that
we have used to derive our ERF. The US-EPA slope fac-
tor is 10 (mg:kg/g)−1, 3.7 times higher than our ERF of
2,692 (mg/kg/d)−1. This slope factor would estimate 3.7
times more risk and impacts. Hence, the uncertainty
conveyed by our ERFs would imply an underestimation
of the risks.
Uncertainties related to exposure estimations via blood
chlordecone measurements have been described in Part
1. Briefly: the age groups of men before and after 2003
do not overlap (20–44 years before 2003 and > 44 years
after 2003), and those of women are limited to the range
17–45 years. Newborn exposure data include girls and
boys. The numbers of individuals are small and mostly
smaller before 2003 than after. It is not possible to know
in which direction these uncertainties affect the quanti-
tative results. However the age group difference for men
before and after 2003 may explain why their exposures
have decreased more than for women and their children.
That would imply that men younger than 44 years work-
ing outside the agricultural sector are more exposed than
those over 44 years.
The population data come from INSEE, the French
official census institution [28]. Their uncertainties are
insignificant compared to the other uncertainties.
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In our calculation we used blood chlordecone concentra-
tions because they seem to better reflect actual exposures
of the population than ingestion doses which have been
shown to be poorly correlated with blood chlordecone [20].
However, important work of estimating ingestion doses has
been produced by the French Agency for Environmental
and Health Safety [6, 42, 43]. It would be therefore in-
teresting to compare the results obtained with the blood
chlordecone (our assessment) to results that would be ob-
tained with the ingestion dose data by following the same
procedure. Unfortunately, there are no ingestion dose data
before 2005. The evaluation of benefits attributable to pre-
vention therefore is not possible with these data. Moreover
the assessment of impacts on cognitive development is
not possible since by definition there is no ingestion
dose in utero.
The concept of DALYs has been used since the 1990s
by WHO to measure the global burden of disease. This
indicator is widely recognized and used in health eco-
nomic studies. The DALY/case values used here come
from French statistics published by WHO [32, 33]. It in-
cludes two components: the years of life lost because of
premature death and an adjustment for the years lived
with the disease. Medical expenses, loss of productivity
and insurance payments are not taken into account. This
has the effect of underestimating the total cost, espe-
cially in the case of prostate cancer, because the annual
number of incident cases of this disease is generally
greater than the annual number of deaths.
The effects of chlordecone on cognitive development
yield the highest cost contribution. The ERF is 0.32 IQ
points lost per μg/l of cord blood chlordecone. By com-
parison the ERF for mercury is 4 times higher with 1.395
IQ points lost per μg/l in cord blood mercury [39]. The
one for lead is less directly comparable since it is related
to blood lead levels of children several years old, not
newborns; it is 3.9 IQ points lost per ug/l for exposures
between 24 and 100 μg/l [38]. Per μg/l in blood, chlorde-
cone is less toxic for cognitive development than mercury
and lead. In the original study on chlordecone, mercury
and lead were also measured in cord blood along with
other chemicals: PCB153 (polychlorinated biphenyl con-
gener 153), p, p-DDE (dichlorodiphenyl Dichloroethylene)
and DHA (docosahexaenoic acid). If mercury and lead
had been found to be correlated with ASQ score for fine
motor skills, it would have yielded a direct link between
that score and IQ points. But with the exception of
PCB153 and chlordecone none of these chemicals was
correlated with the ASQ score for fine motor skills (with a
p <0.2) [13]. Even though this may raise doubts about the
equivalence between IQ point at 7 years and fine motor
skills measured at 18 months by the ASQ score, a lack of
such correlation for lead and mercury does not imply that
chlordecone will not be correlated with IQ score at 7 years.
Its low-dose toxicity for the nervous system has been
shown by mechanistic studies (see Part 1). Today this un-
certainty is difficult to reduce. Our assessment uses the
available and relevant data and our results should be up-
dated when new knowledge emerges.
The estimated fraction of collective exposure is uncer-
tain because the means and standard deviations of blood
chlordecone concentrations were not published in the
original articles (except Multigner 2006). We used the
weighted average of values of each exposure groups de-
fined for each population category (see Part 1, Table 7).
For example, the average blood chlordecone concentra-
tion for men 20–45 years before 2003 obtained by our
weighted average is 7.1 μg/l. This value is close to the
geometric mean published by the authors 8.4 μg/l [14],
the only comparison point available. Standard deviations
are determined by successive iterations to fit a log normal
distribution to the values of known exposure quartiles.
Only the use of original individual data would have re-
duced this uncertainty, but unfortunately they are not ac-
cessible. However, the impacts and costs with threshold
are not very different from those without threshold, and
the gains resulting from preventive actions are almost the
same. This can be explained by the fact that the Fthr of
newborns is much higher than the women’s Fthr because
the threshold for newborns is lower, together with the very
high cost contribution of cognitive development. Overall,
the inclusion of a no-effect threshold reduces the costs of
the health impacts by a factor 0.7 before and by a factor
0.54 after the intervention. These results seem specific to
the particular distribution of measured blood chlordecone
concentrations. Before 2003 over 50 % of the impacts are
in the most exposed group (Group 5) regardless of the ef-
fect considered (see Additional file 1 tables A to J). This
proportion rises to over 80 % of impacts after 2003.
The costs of the exposure reduction program come
from the balance sheet of the 1st Chlordecone Plan dur-
ing the period 2008–2010 [40]. We do not have data for
2003–2008, and we considered that the annual expenses
were the same as for 2008–2010, with adjustment for in-
flation. Nevertheless, these costs are probably underesti-
mated because, for example, the work of the civil service
and local authorities dealing with this problem is not
included.
Our comparison of costs and benefits indicates that
the health benefits far outweigh the costs of the preven-
tion program, whether evaluated with or without thresh-
old. Kidney damage accounts for only 0.5 to 1 % of total
health benefits and excluding it would not significantly
change the conclusion. The same holds for cognitive de-
velopment impacts: they account only for around 20 %
of the total benefits due to the prevention program, and
omitting them would not make the benefits smaller than
the cost.
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Not all prevention actions have the same efficacy, and
it would be desirable to know the costs and benefits of
individual actions. Unfortunately there are no data for
that; the program can only be evaluated as a package.
Conclusion
This work presents a double originality. This is the
first quantitative health risk assessment with low dose
exposure-response functions derived for a non-mutagenic
chemical, an approach increasingly recommended for
endocrine disrupters. It is also the first work to monetize
health impacts of chlordecone. Our approach provides
valuable information for public health decision making. Its
flexibility allows comparing basic assumptions such as the
existence of a no-effect threshold. It also allows a compari-
son of the cost of preventive actions with the corresponding
health benefits. Finally the results facilitate the prioritization
of health safety actions. For example, according to our
results, pregnant women should be targeted by preventive
actions because of the high social cost of development im-
pairment and also because exposures of mothers and new-
borns are lowered less rapidly than others. Our quantitative
approach is generally recommended for environmental fac-
tors to which populations are already exposed.
Actions for reducing chlordecone exposure in Guadeloupe
seem effective and appear justified by their benefits, whether
or not one assumes a no-effect threshold. The persistence of
chlordecone in soil calls for continuing these actions in
the long term. Determining the level of expenditures
for the optimal reduction of exposures would necessi-
tate more detailed assessments than we have presented.
As a first approximation, maintaining the commitments
of the first Chlordecone Plan appears to be a good policy
to prevent exposures from rising again to levels existing
before 2003. Repetitive monitoring of blood chlordecone
concentrations in a representative population sample
would be very useful for the management and assess-
ment of these actions. The monitoring of food should
be maintained in order to keep contaminated food out
of distribution channels, but the utility of such data
(ingestion dose) for risk assessment is doubtful in the
case of chlordecone.
Epidemiological surveys would be needed to study the
role of chlordecone in effects that have not been taken
into account here for lack of knowledge about exposure-
response relationships (neurotoxicity, autoimmune diseases,
and other developmental effects). Toxicological knowledge
available about chlordecone is old and mainly limited to
acute effects. It would be useful to provide mechanistic
studies on these “orphan” effects before implementing
epidemiological studies. Finally, an extended follow-up
of children in the TIMOUN cohort would allow redu-
cing the uncertainty about the effect of chlordecone on
cognitive development.
When making an assessment for environmental factors
to which populations are already exposed, focusing only
on the so called « critical effect » of a chemical can dra-
matically underestimate the total impacts and health
costs. Another source of strong underestimation is the
use of average values instead of detailed exposure distri-
butions. The quantitative approach that we propose for
non-genotoxic effects allows to avoid these biases.
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